| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 24.05.
| Zalicus Is Locked And Loaded: What You Need To Know | | 2 | Seeking Alpha |
| 24.05.
| Why Buying 'Market Outperform' Zalicus At A Discount Is Savvy | | 2 | Seeking Alpha |
| 09.05.
| Zalicus to Present at Two Upcoming Investor Conferences | | 26 | Business Wire |
| Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers
and develops novel treatments for patients suffering from pain and
immuno-inflammatory diseases...
Mehr lesen zu:
Zalicus to Present at Two Upcoming Investor Conferences | |
| 07.05.
| Investors look to Lighten Up on Shares of Zalicus, Shares Down 7.8% | | 1 | SmarTrend |
| 03.05.
| Biotech Industry Will Look to Benefit From New U.S. Patent System / The Paragon Report Provides Stock Research on AEterna Zentaris and Zalicus | | 34 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/03/12 -- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date....
Mehr lesen zu:
Biotech Industry Will Look to Benefit From New U.S. Patent System / The Paragon Report Provides Stock Research on AEterna Zentaris and Zalicus | |
| 03.05.
| Zalicus Reports Financial Results for the First Quarter 2012 | | 35 | Business Wire |
| Continued Pipeline Progress
Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the
first quarter ended March 31, 2012.
...
Mehr lesen zu:
Zalicus Reports Financial Results for the First Quarter 2012 | |
| 02.05.
| Zalicus (ZLCS) Advances Z160 into Phase 2a Trials | | 1 | StreetInsider.com |
| 02.05.
| Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, into Multiple Phase 2a Clinical Trials for the Treatment of Pain | | 28 | Business Wire |
| Optimal Formulation Selected For Clinical Use First Phase 2a Clinical
Trial to Initiate Third Quarter 2012
Zalicus
Inc. (NASDAQ: ZLCS), a biopharmaceutical...
Mehr lesen zu:
Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, into Multiple Phase 2a Clinical Trials for the Treatment of Pain | |
| 01.05.
| Zalicus completes enrollment in Phase IIb rheumatoid arthritis trial | | 3 | Pharma Bus Review |
| 30.04.
| Zalicus Completes Patient Enrollment in Phase 2b Clinical Trial of Synavive in Rheumatoid Arthritis | | 43 | Business Wire |
| Top-line Data Planned for Third Quarter 2012
Zalicus
Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and
develops novel treatments...
Mehr lesen zu:
Zalicus Completes Patient Enrollment in Phase 2b Clinical Trial of Synavive in Rheumatoid Arthritis | |
| 26.04.
| Zalicus Provides Oncology Research Collaboration Update | | 34 | Business Wire |
| Zalicus
Inc. (NASDAQ: ZLCS) provided an update today on its research
collaboration with Novartis, based on its combination High Throughput
Screening (cHTS) platform.
...
Mehr lesen zu:
Zalicus Provides Oncology Research Collaboration Update | |
| 05.04.
| Zalicus Discovers Novel Multi-Target Mechanism for the Treatment of Multiple Myeloma | | 45 | Business Wire |
| New Findings Published in Molecular Cancer Therapeutics
Demonstrate Novel and Selective Synergy for Adenosine A2A and Beta-2
Adrenergic Receptor Agonists in Combination...
Mehr lesen zu:
Zalicus Discovers Novel Multi-Target Mechanism for the Treatment of Multiple Myeloma | |
| 22.03.
| TREAT Act Poised to Revolutionize the Biotechnology Industry / Five Star Equities Provides Stock Research on Avanir Pharmaceuticals & Zalicus | | 58 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 03/22/12 -- In recent years, smaller biotechnology companies have received less funding from venture capitalists than in years past. According to the Biotechnology...
Mehr lesen zu:
TREAT Act Poised to Revolutionize the Biotechnology Industry / Five Star Equities Provides Stock Research on Avanir Pharmaceuticals & Zalicus | |
| 09.03.
| COMBINATORX, INC - 10-K, Annual Report | | - | SEC Filings |
| 07.03.
| Zalicus Reports Financial Results for the Fourth Quarter and Year End 2011 | | 23 | Business Wire |
| Provides Key Goals for 2012
Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the
fourth quarter and year ended December 31, 2011.
...
Mehr lesen zu:
Zalicus Reports Financial Results for the Fourth Quarter and Year End 2011 | |
| 05.03.
| Zalicus Successfully Completes Phase 1 Clinical Study with Reformulated Z160 | | 29 | Business Wire |
| Advancing Into Phase 2 for Neuropathic Pain with Improved Formulation
in Second Half of 2012
Zalicus
Inc. (NASDAQ: ZLCS) a biopharmaceutical...
Mehr lesen zu:
Zalicus Successfully Completes Phase 1 Clinical Study with Reformulated Z160 | |
| 02.03.
| Growing Medical Need for Cancer and Inflammation Treatment Benefits Cell Therapeutics and Zalicus / Five Star Equities Provides Stock Research on Cell Therapeutics & Zalicus | | 106 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 03/02/12 -- Biotechnology shares have been on impressive run of late. Led by the growing popularity in early stage biotechnology companies, the iShares Nasdaq Biotechnology...
Mehr lesen zu:
Growing Medical Need for Cancer and Inflammation Treatment Benefits Cell Therapeutics and Zalicus / Five Star Equities Provides Stock Research on Cell Therapeutics & Zalicus | |
| 29.02.
| Zalicus to Present at Cowen and Company 32nd Annual Health Care Conference | | 41 | Business Wire |
| Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers
and develops novel treatments for patients suffering from pain and
immuno-inflammatory diseases...
Mehr lesen zu:
Zalicus to Present at Cowen and Company 32nd Annual Health Care Conference | |
| 15.02.
| Zalicus Publishes Data on Novel Ion Channel Compounds | | 33 | Business Wire |
| - New Paper Published in Science Translational Medicine Reports
Anti-Epileptic Activity of Z944, a Novel Oral, T-type Calcium Channel
Blocker in Clinical Development for...
Mehr lesen zu:
Zalicus Publishes Data on Novel Ion Channel Compounds | |
| 09.02.
| Zalicus and Hydra Collaborate to Advance Novel Ion Channel Product Candidates for the Treatment of Pain | | 47 | Business Wire |
| Zalicus
Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain and
immuno-inflammatory diseases...
Mehr lesen zu:
Zalicus and Hydra Collaborate to Advance Novel Ion Channel Product Candidates for the Treatment of Pain | |
